Benefit of a flash dose of corticosteroids in digestive surgical oncology: a multicenter, randomized, double blind, placebo-controlled trial (CORTIFRENCH).

Date publication

août 2022

Journal

BMC cancer

Auteurs

Membres identifiés du Cancéropôle Est :
Pr AYAV Ahmet , Dr FOURNEL Isabelle , Pr ORTEGA DEBALLON Pablo , Dr ORRY David , Dr LAKKIS Zaher

Tous les auteurs :
Magnin J, Fournel I, Doussot A, Régimbeau JM, Zerbib P, Piessen G, Beyer-Berjot L, Deguelte S, Lakkis Z, Schwarz L, Orry D, Ayav A, Muscari F, Mauvais F, Passot G, Trelles N, Venara A, Benoist S, Messager M, Fuks D, Borraccino B, Trésallet C, Valverde A, Souche FR, Herrero A, Gaujoux S, Lefevre J, Bourredjem A, Cransac A, Ortega-Deballon P

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/35999521

Résumé

The modulation of perioperative inflammation seems crucial to improve postoperative morbidity and cancer-related outcomes in patients undergoing oncological surgery. Data from the literature suggest that perioperative corticosteroids decrease inflammatory markers and might be associated with fewer complications in esophageal, liver, pancreatic and colorectal surgery. Their benefit on cancer-related outcomes has not been assessed.

Mots clés

Digestive surgical oncology, Perioperative corticosteroids, Postoperative morbidity, Randomized placebo-controlled trial, cancer-related outcomes

Référence

BMC Cancer. 2022 08 23;22(1):913